Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens

Sokhela, S., Venter, W. D. F., Bosch, B., Woods, J., McCann, K., Akpomiemie, G., Chandiwana, N., Mashabane, N., Tembo, A., Simmons, B., Lalla-Edward, S., Siedner, M. J., Sinxadi, P., Hermans, L., Fairlie, L., Vos, A., Abrams, E., Manne-Goehler, J. M., Moorhouse, M., … Hill, A. (2024). Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens. Open Forum Infectious Diseases, 11(3). https://doi.org/10.1093/ofid/ofae007
Authors:
Simiso Sokhela
Willem D F Venter
Bronwyn Bosch
Joana Woods
Kaitlyn McCann
Godspower Akpomiemie
Nomathemba Chandiwana
Nkuli Mashabane
Angela Tembo
Bryony Simmons
Samanta Lalla-Edward
Mark J Siedner
Phumla Sinxadi
Lucas Hermans
Lee Fairlie
Alinda Vos
Elaine Abrams
Jennifer M Manne-Goehler
Michelle Moorhouse
Polly Clayden
Shane Norris
Ambar Qavi
Matthew Chersich
Masebole Masenya
Natasha Arulappan
Andrew Hill
Affiliated Authors:
Elaine Abrams
Author Keywords:
dolutegravir
tenofovir
obesity
suppression
resistance
Publication Type:
Article
Unique ID:
10.1093/ofid/ofae007
PMID:
Publication Date:
Data Source:
PubMed

Record Created: